A new algorithm analyzes patterns in mutational profiles to identify cancer patients with underlying defects in DNA repair machinery, guiding targeted therapies.

Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments.  Researchers at the University of Texas MD Anderson Cancer Center have discovered that these cells alter epigenetic programing to temporarily become drug-resistant. The resistant cells switch metabolic pathways from glycolysis to mitochondrial respiration, but a new...

HDPCR Tick-Borne Pathogen (TBP) Panel is a multiplexPCR test that detects nine of the most common tick-borne pathogens in a single test.

Researchers from the Wellcome Sanger Institute, GlaxoSmithKline, EMBL-EBI, and Open Targets conducted one of the largest CRISPR screens of cancer genes to date.

Sophia Genetics has obtained the CE-IVD marking for its Solid Tumor Solution (STS), a molecular diagnostic application designed to precisely detect and characterize all types of genomic alterations in 42 clinically relevant genes associated with a range of solid tumors. Those solid tumors include lung, colorectal, skin and brain cancers. According...

The AI platform from Notable completed personalized treatment recommendations for all 20 patients within 30 days demonstrating both a positive and negative predictive value average of 84 percent.

CRC tumors can switch off expression of a cell surface molecule that is a key target of immunotherapy, thus preventing the treatment from working.

Clinico-genomic research study aims to improve personalized treatments for people with multiple sclerosis DNAnexus, UPMC, and Sutter Health network said today they have launched a large-scale clinico-genomic multiple sclerosis (MS) research study aimed at improving personalized treatments for people with the group of 30+ inherited neuromuscular diseases. Under the collaboration, whose...

Thermo Fisher Scientific will combine its liquid chromatography-mass spectrometry (LC-MS) instrumentation with NX Prenatal’s NeXosome platform to develop proteomics assays designed to offer noninvasive risk assessments of pregnancy outcomes, through a collaboration whose value was not disclosed. The collaboration aims to develop diagnostics to monitor fetal health in utero and...

Five years after the introduction of the $1,000 genome, the sequencing field remains rife with chatter about pushing the cost much lower—not only to $100 (and why the world may not be ready for it), but as far down as $10. Coming close to that $100 benchmark last year was Veritas Genetics....